Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Common Equity (2016 - 2021)

Historic Common Equity for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $1.3 billion.

  • Neurocrine Biosciences' Common Equity rose 6735.05% to $1.3 billion in Q3 2021 from the same period last year, while for Sep 2021 it was $1.3 billion, marking a year-over-year increase of 6735.05%. This contributed to the annual value of $1.1 billion for FY2020, which is 7682.52% up from last year.
  • Neurocrine Biosciences' Common Equity amounted to $1.3 billion in Q3 2021, which was up 6735.05% from $1.3 billion recorded in Q2 2021.
  • In the past 5 years, Neurocrine Biosciences' Common Equity registered a high of $1.3 billion during Q3 2021, and its lowest value of $247.1 million during Q1 2017.
  • In the last 5 years, Neurocrine Biosciences' Common Equity had a median value of $483.7 million in 2019 and averaged $651.5 million.
  • Per our database at Business Quant, Neurocrine Biosciences' Common Equity tumbled by 4015.36% in 2017 and then soared by 7682.52% in 2020.
  • Neurocrine Biosciences' Common Equity (Quarter) stood at $372.1 million in 2017, then grew by 29.19% to $480.8 million in 2018, then skyrocketed by 32.48% to $636.9 million in 2019, then skyrocketed by 76.83% to $1.1 billion in 2020, then rose by 19.52% to $1.3 billion in 2021.
  • Its Common Equity stands at $1.3 billion for Q3 2021, versus $1.3 billion for Q2 2021 and $1.2 billion for Q1 2021.